STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 241

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 241

pharmaphorum

JANUARY 15, 2021

Now, speaking to him as the first vaccines are deployed in the UK, he highlights the importance of GSK’s employees and culture to the future of the company post-COVID. With the new goals, GSK aims to have a net zero impact on climate and a net positive impact on nature by 2030.

Vaccines 105

Vaccines Drug Development 105

Express Pharma

JULY 10, 2024

India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. Brimming with potential As per an Invest India report of 2023, the Indian Bioeconomy, valued at $137 billion in 2023, is targeted to reach $150 billion by 2025 and $300 billion by 2030. billion monthly.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Vaccines 111

Vaccines Immunity Immunization Drug Development 111

PharmaShots

APRIL 3, 2023

of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

Express Pharma

FEBRUARY 5, 2025

37 per cent of respondents in an EY-OPPI report view competition from generic drugs and biosimilars as a top trend, while 30 per cent cite the patent cliff as a significant concern (2). A deal that exemplifies and reflects most of the industry dynamics mentioned earlier is Mankind Pharmas acquisition of Bharat Serums and Vaccines in 2024.

Biosimilars 90

Biosimilars Vaccines Drug Development 90

Express Pharma

MARCH 21, 2025

Hyderabad leads in bulk drug manufacturing, advanced biopharma research, and vaccine innovation, serving as the base for renowned international players. As Hyderabad aims to expand its life sciences sector from $100 billion to $250 billion by 2030, adopting an integrated research campus model could be the key to achieving this growth.

Vaccines 66

Vaccines Biosimilars Drug Development 66